No Cover Image

Journal article 489 views

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity

David M Williams, Matthew Staff, Steve Bain Orcid Logo, Thinzar Min

Endocrinology, Volume: 18, Issue: 1, Start page: 43

Swansea University Authors: Steve Bain Orcid Logo, Thinzar Min

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.17925/ee.2022.18.1.43

Abstract

There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective the...

Full description

Published in: Endocrinology
ISSN: 2752-5457 2752-5457
Published: Touch Medical Media, Ltd. 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60990
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-08-31T14:05:12Z
last_indexed 2023-01-13T19:21:31Z
id cronfa60990
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-09-13T13:52:30.0838652</datestamp><bib-version>v2</bib-version><id>60990</id><entry>2022-08-31</entry><title>Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>27cba511a4800fefddb6885ffffdb8b2</sid><firstname>Thinzar</firstname><surname>Min</surname><name>Thinzar Min</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-08-31</date><deptcode>BMS</deptcode><abstract>There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective therapies for obesity. Glucagon-like peptide-1 receptor analogues (GLP-1RAs) are licensed for the treatment of type 2 diabetes (T2D), and there is substantial evidence that these drugs not only improve cardiovascular outcomes but also promote weight loss. More recent evidence supports the use of the GLP-1RAs liraglutide and semaglutide in people with obesity without T2D. This article discusses the results of the major cardiovascular outcome trials for GLP-1RAs in people with T2D, the SCALE Obesity and Prediabetes study (Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE&#x2122; - Obesity and Pre-diabetes; ClinicalTrials.gov identifier: NCT01272219; investigating liraglutide) and the STEP studies (Semaglutide treatment effect in people with obesity; assorted studies; investigating subcutaneous semaglutide). We also highlight the importance of a cost-effective approach to obesity pharmacotherapy. Clinicians should consider the use of GLP-1RAs in people with obesity, especially those with T2D or other obesity-related diseases, such as hypertension and dyslipidaemia. Ongoing trials, as well as clinical and cost-effectiveness appraisals, are anticipated over the next 12 months, and their findings may change the current landscape of obesity pharmacotherapy. [Abstract copyright: &#xA9; Touch Medical Media 2022.]</abstract><type>Journal Article</type><journal>Endocrinology</journal><volume>18</volume><journalNumber>1</journalNumber><paginationStart>43</paginationStart><paginationEnd/><publisher>Touch Medical Media, Ltd.</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2752-5457</issnPrint><issnElectronic>2752-5457</issnElectronic><keywords>obesity, liraglutide, weight management, weight loss, type 2 diabetes, semaglutide, overweight, diabetes mellitus, Glucagon-like peptide-1 (GLP-1) receptor analogue</keywords><publishedDay>17</publishedDay><publishedMonth>3</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-03-17</publishedDate><doi>10.17925/ee.2022.18.1.43</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-09-13T13:52:30.0838652</lastEdited><Created>2022-08-31T14:58:25.9288791</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>David M</firstname><surname>Williams</surname><order>1</order></author><author><firstname>Matthew</firstname><surname>Staff</surname><order>2</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>3</order></author><author><firstname>Thinzar</firstname><surname>Min</surname><order>4</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2022-09-13T13:52:30.0838652 v2 60990 2022-08-31 Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 27cba511a4800fefddb6885ffffdb8b2 Thinzar Min Thinzar Min true false 2022-08-31 BMS There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective therapies for obesity. Glucagon-like peptide-1 receptor analogues (GLP-1RAs) are licensed for the treatment of type 2 diabetes (T2D), and there is substantial evidence that these drugs not only improve cardiovascular outcomes but also promote weight loss. More recent evidence supports the use of the GLP-1RAs liraglutide and semaglutide in people with obesity without T2D. This article discusses the results of the major cardiovascular outcome trials for GLP-1RAs in people with T2D, the SCALE Obesity and Prediabetes study (Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE™ - Obesity and Pre-diabetes; ClinicalTrials.gov identifier: NCT01272219; investigating liraglutide) and the STEP studies (Semaglutide treatment effect in people with obesity; assorted studies; investigating subcutaneous semaglutide). We also highlight the importance of a cost-effective approach to obesity pharmacotherapy. Clinicians should consider the use of GLP-1RAs in people with obesity, especially those with T2D or other obesity-related diseases, such as hypertension and dyslipidaemia. Ongoing trials, as well as clinical and cost-effectiveness appraisals, are anticipated over the next 12 months, and their findings may change the current landscape of obesity pharmacotherapy. [Abstract copyright: © Touch Medical Media 2022.] Journal Article Endocrinology 18 1 43 Touch Medical Media, Ltd. 2752-5457 2752-5457 obesity, liraglutide, weight management, weight loss, type 2 diabetes, semaglutide, overweight, diabetes mellitus, Glucagon-like peptide-1 (GLP-1) receptor analogue 17 3 2022 2022-03-17 10.17925/ee.2022.18.1.43 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-09-13T13:52:30.0838652 2022-08-31T14:58:25.9288791 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine David M Williams 1 Matthew Staff 2 Steve Bain 0000-0001-8519-4964 3 Thinzar Min 4
title Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
spellingShingle Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
Steve Bain
Thinzar Min
title_short Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
title_full Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
title_fullStr Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
title_full_unstemmed Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
title_sort Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
27cba511a4800fefddb6885ffffdb8b2
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
27cba511a4800fefddb6885ffffdb8b2_***_Thinzar Min
author Steve Bain
Thinzar Min
author2 David M Williams
Matthew Staff
Steve Bain
Thinzar Min
format Journal article
container_title Endocrinology
container_volume 18
container_issue 1
container_start_page 43
publishDate 2022
institution Swansea University
issn 2752-5457
2752-5457
doi_str_mv 10.17925/ee.2022.18.1.43
publisher Touch Medical Media, Ltd.
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 0
active_str 0
description There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective therapies for obesity. Glucagon-like peptide-1 receptor analogues (GLP-1RAs) are licensed for the treatment of type 2 diabetes (T2D), and there is substantial evidence that these drugs not only improve cardiovascular outcomes but also promote weight loss. More recent evidence supports the use of the GLP-1RAs liraglutide and semaglutide in people with obesity without T2D. This article discusses the results of the major cardiovascular outcome trials for GLP-1RAs in people with T2D, the SCALE Obesity and Prediabetes study (Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE™ - Obesity and Pre-diabetes; ClinicalTrials.gov identifier: NCT01272219; investigating liraglutide) and the STEP studies (Semaglutide treatment effect in people with obesity; assorted studies; investigating subcutaneous semaglutide). We also highlight the importance of a cost-effective approach to obesity pharmacotherapy. Clinicians should consider the use of GLP-1RAs in people with obesity, especially those with T2D or other obesity-related diseases, such as hypertension and dyslipidaemia. Ongoing trials, as well as clinical and cost-effectiveness appraisals, are anticipated over the next 12 months, and their findings may change the current landscape of obesity pharmacotherapy. [Abstract copyright: © Touch Medical Media 2022.]
published_date 2022-03-17T04:19:33Z
_version_ 1763754297081724928
score 11.012678

Similar Items